Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study

Gynecol Oncol. 1997 Apr;65(1):94-101. doi: 10.1006/gyno.1996.4577.


Background: Twenty-seven ovarian cancer patients who failed chemotherapy entered a phase I/II trial of intraperitoneal 177Lu-CC49 antibody.

Methods: Patients had disease confined to the abdominal cavity +/- retroperitoneal lymph nodes, adequate organ function, and no previous radiation.

Results: The most common side effects were delayed, transient arthralgia (10/27) and marrow suppression with 1.665 GBq/m2 (45 mCi/m2), which was considered the maximum tolerated dose. One of thirteen patients with gross disease had >50% tumor reduction after therapy, whereas most others with gross disease progressed (one went off study with stable disease at 11 weeks). Seven of nine patients with <1-cm nodules progressed in < or =21 months, and two of nine remain without evidence of disease at 4 to 5 months. Of patients with microscopic or occult disease, one relapsed at 10 months and four of five remain without evidence of disease at >6 to 35 months.

Conclusions: Marrow suppression was the dose-limiting toxic effect of intraperitoneal immunotherapy with 177Lu-CC49. Antitumor effects were noted against chemotherapy-resistant ovarian cancer, even at lower dose levels, and resulted in prolonged disease-free survival of most patients with microscopic disease. This form of treatment deserves further study.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / administration & dosage*
  • Arthralgia / etiology
  • Bone Marrow / pathology
  • Bone Marrow / radiation effects
  • Disease Progression
  • Dose-Response Relationship, Radiation
  • Female
  • Humans
  • Injections, Intraperitoneal
  • Lutetium*
  • Middle Aged
  • Ovarian Neoplasms / blood
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / radiotherapy*
  • Platelet Count
  • Radioimmunotherapy / adverse effects
  • Radioimmunotherapy / methods
  • Radioimmunotherapy / standards*
  • Radioisotopes*


  • Antibodies, Monoclonal
  • Radioisotopes
  • Lutetium